PTPaulina Patrycja Turzyńska

Paulina Patrycja Turzyńska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paulina Patrycja Turzyńska has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer-Associated Osteoporosis and Treatment-Induced Bone Loss: Mechanisms, Prevention, and Therapeutic Strategies

    by Paulina Patrycja Turzyńska

    Background. Cancer-associated osteoporosis and cancer treatment-induced bone loss (CTIBL) are important causes of skeletal morbidity. Fracture risk reflects the interaction of treatment-related bone loss, endocrine disruption, and deterioration of the muscle–bone unit and may not be adequately captured by bone mineral density (BMD) alone. Aim. To critically synthesize current evidence on the mechanisms, risk assessment, prevention, and treatment of cancer-associated osteoporosis and CTIBL. Material and methods. A narrative review of international guidelines, randomized trials, systematic reviews, meta-analyses, and key observational studies was conducted. Results. Aromatase inhibition and androgen deprivation are major drivers of CTIBL, with additional risk from glucocorticoids, gonadal dysfunction, sarcopenia, and physical deconditioning. Management requires integration of BMD with clinical and treatment-specific fracture risk. Bisphosphonates and denosumab remain the principal pharmacological strategies, while structured exercise complements treatment by targeting the muscle–bone unit. Treatment selection, safety, and appropriate therapeutic sequencing are essential for effective fracture prevention. Conclusions. Cancer-associated skeletal fragility should be regarded as a dynamic, treatment-modified fracture-risk state rather than a BMD-defined complication. Integrating treatment-specific risk assessment, bone-directed therapy, and preservation of musculoskeletal function provides a coherent framework for fracture prevention throughout cancer care.

  • Open Access

    SKIN CANCER RISK IN WATER SPORTS PARTICIPANTS: ULTRAVIOLET RADIATION EXPOSURE AND PHOTOPROTECTIVE BEHAVIORS IN THE CONTEXT OF CHALLENGES AND PREVENTIVE STRATEGIES – A NARRATIVE REVIEW

    by Weronika Martynowska, Alicja Graczyk, Michał Hajt, Dastin Misiaszek, Anna Wolszczak, Jakub Motor, Piotr Ciecierski, Natalia Grabowska, Paulina Turzyńska, Mateusz Martynowski

    Background: Water sports create a unique "high-exposure trap," significantly increasing the risk of melanoma (MSC) and non-melanoma skin cancer (NMSC) due to intense ambient UV radiation and surface reflectance. Objective: To evaluate specific risk factors and analyze the mechanical, physiological, and behavioral barriers to effective photoprotection in maritime environments. Methods: A narrative review of PubMed, Scopus, and Web of Science (February 2026) focusing on UVR exposure and protective behaviors in aquatic athletes. Results: Participants face synergistic UVR doses from direct solar radiation and surface albedo (up to 25%). Diagnosis of early damage is often hindered by the cooling effects of water/wind, which mask erythema. Standard photoprotection frequently fails due to sunscreen wash-off, chemical conjunctivitis, and thermoregulatory constraints of clothing. Professional athletes exhibit a higher incidence of field cancerization and a significant "knowledge-behavior gap" compared to recreational users. Conclusion: Generic guidelines are inadequate for the maritime setting. Specialized protocols are required, including friction-resistant sunscreen formulations and optimized UPF 50+ apparel. Mandatory dermatological screening and targeted education are essential to mitigate oncological morbidity in this high-risk population.

  • Open Access

    NEURO-ENDOCRINE-IMMUNE CROSSTALK IN CHRONIC DISEASES: AN INTEGRATIVE REVIEW OF MOLECULAR MECHANISMS, BIOMARKERS, AND PREVENTIVE STRATEGIES

    by Paulina Patrycja Turzyńska, Marcjanna Maria Liedtke, Alicja Biskup, Agata WnęK, Weronika Martynowska, Dastin Misiaszek, Natalia Grabowska, Anna Wolszczak

    Background: The growing burden of chronic non-communicable diseases has highlighted the importance of the neuro-endocrine-immune (NEI) axis as a central regulatory network integrating neural, endocrine, and immune signaling to maintain physiological homeostasis and coordinate adaptive responses to internal and environmental challenges. Increasing evidence indicates that disruption of this bidirectional communication contributes to chronic low-grade inflammation, impaired stress adaptation, and the development of multiple chronic diseases. Objective: This integrative review aims to synthesize current evidence on the molecular mechanisms, regulatory networks, biomarkers, and translational implications of neuro-endocrine-immune crosstalk, with particular emphasis on its relevance for preventive strategies and personalized medicine. Materials and Methods: An integrative review of peer-reviewed literature indexed in PubMed, Scopus, and Web of Science was conducted. The available evidence was synthesized to identify key molecular pathways, neuroimmune regulatory mechanisms, environmental sensing pathways, and clinically relevant biomarkers associated with neuro-endocrine-immune (NEI) dysregulation. Results: The available evidence indicates that disruption of NEI crosstalk promotes persistent inflammatory activation, autonomic imbalance, impaired glucocorticoid signaling, and immune dysregulation, thereby contributing to the initiation and progression of major chronic diseases. Inflammatory mediators, cortisol dynamics, autonomic indices, microbiota-derived metabolites, and environmental sensing pathways have emerged as promising biomarkers and therapeutic targets for disease prevention and risk stratification. Conclusions: The NEI axis represents a fundamental systems-level interface linking environmental exposures, stress responses, and chronic disease development. A deeper understanding of NEI crosstalk provides a scientific basis for identifying clinically relevant biomarkers and supports the development of predictive, preventive, personalized, and participatory strategies for chronic disease prevention and management.

  • Open Access

    INTEGRATED SCAR MANAGEMENT: CURRENT EVIDENCE ON CONSERVATIVE, REGENERATIVE, AND LASER-BASED THERAPIES - A NARRATIVE REVIEW

    by Paulina Patrycja Turzyńska, Marcjanna Maria Liedtke

    Pathological scarring remains a major challenge in reconstructive, plastic, and aesthetic medicine owing to the complex biology of wound healing, marked heterogeneity of scar phenotypes, and the lack of universally effective treatment strategies. Advances in regenerative medicine and laser technologies have expanded therapeutic options while increasing the need for individualized, evidence-based treatment. This narrative review synthesizes current evidence on conservative, regenerative, and laser-based therapies for scar management, emphasizing their biological rationale, clinical effectiveness, limitations, and role within contemporary multimodal treatment strategies. The literature was identified through searches of PubMed, Scopus, and Web of Science, with priority given to systematic reviews, meta-analyses, randomized controlled trials, international guidelines, and other high-quality evidence. Current evidence indicates that successful scar management depends on matching treatment to scar phenotype and biological activity rather than relying on a single therapeutic modality. Conservative therapies remain the foundation of treatment, whereas regenerative approaches and laser technologies enhance outcomes, particularly when integrated into multimodal protocols. Despite substantial therapeutic progress, heterogeneity of available evidence continues to limit direct comparison and standardization of treatment strategies. Overall, contemporary scar management is evolving toward personalized, mechanism-based approaches that integrate complementary therapies to optimize functional and aesthetic outcomes.

  • Open Access

    Relapse of Dermatomyositis as a Marker of Occult Malignancy: Current Evidence and Clinical Implications.

    by Paulina Patrycja Turzyńska, Marcjanna Maria Liedtke, Weronika Martynowska, Mateusz Martynowski

    Background. Dermatomyositis (DM) is an inflammatory myopathy strongly associated with malignancy. Although cancer screening at disease onset is well established, the significance of disease relapse as a marker of occult malignancy remains uncertain. Aim. To summarize current evidence on the relationship between dermatomyositis relapse and malignancy, focusing on epidemiology, serological risk stratification, pathophysiological mechanisms, and cancer-screening strategies. Material and methods. A narrative review of studies, systematic reviews, meta-analyses, and international guidelines published between 2001 and 2026 was conducted using PubMed, Scopus, and Web of Science databases. Results. Malignancy risk is highest during the first years after DM onset and is particularly increased in patients with anti-TIF1γ and anti-NXP2 antibodies. Emerging evidence suggests that disease relapse, progressive weakness, and treatment refractoriness may precede occult malignancy or indicate cancer recurrence. Current recommendations support risk-adapted screening based on clinical, demographic, and serological factors. Conclusions. Relapse of dermatomyositis should prompt renewed evaluation for underlying malignancy, particularly in high-risk patients. Individualized screening strategies and autoantibody profiling remain essential for the early detection of cancer-associated disease.

  • Open Access

    Immunometabolism and GLP-1 Signaling in Rheumatic Diseases: Molecular Mechanisms, Clinical Implications, and Therapeutic Perspectives

    by Paulina Patrycja Turzyńska

    BackgroundRheumatic diseases are increasingly recognized as disorders driven by both immune dysregulation and profound metabolic alterations. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for obesity and type 2 diabetes, have demonstrated pleiotropic effects extending beyond metabolic control. However, the relationship between immunometabolism and GLP-1 signaling in rheumatic diseases remains incompletely understood. AimTo summarize current evidence on the interplay between immunometabolic pathways and GLP-1 signaling in rheumatic diseases. Material and methodsA narrative review of studies published between 2010 and 2026 was conducted using the PubMed, Scopus, and Web of Science databases. ResultsDysregulated glycolysis, mitochondrial dysfunction, altered lipid metabolism, and hypoxia-driven signaling contribute to chronic inflammation and tissue damage in rheumatic diseases. Key pathways involving AMP-activated protein kinase, mammalian target of rapamycin, hypoxia-inducible factor-1α, and the NLRP3 inflammasome link metabolism to immune activation. Beyond their glucose-lowering effects, GLP-1RAs modulate immune responses, attenuate inflammation, and improve cardiometabolic outcomes. Emerging evidence suggests potential benefits in rheumatoid arthritis, osteoarthritis, psoriasis, and other immune-mediated disorders. ConclusionsImmunometabolism represents a promising therapeutic frontier in rheumatology, positioning GLP-1 signaling at the intersection of metabolism and immune homeostasis. Further mechanistic studies and clinical trials are needed to define the therapeutic role of GLP-1RAs in rheumatic diseases.

  • Open Access

    Nutritional Deficiencies in Crohn’s Disease: Pathogenesis, Clinical Significance, and Therapeutic Management

    by Natalia Grabowska, Alicja Graczyk, Michał Hajt, Dastin Misiaszek, Anna Wolszczak, Jakub Motor, Weronika Martynowska, Piotr Ciecierski, Paulina Turzyńska

    Crohn’s disease (CD) is a chronic, relapsing-remitting inflammatory disorder of the gastrointestinal tract in which impaired nutritional status and nutritional deficiencies are common. This issue is of major clinical relevance, as deficiencies in both macro- and micronutrients not only reflect disease activity but may also influence disease course, treatment efficacy, and patients’ quality of life. The pathogenesis of nutritional deficiencies in Crohn’s disease is multifactorial and includes malabsorption, reduced dietary intake, increased metabolic demand, nutrient loss, and the effects of pharmacotherapy. The most frequently observed deficiencies involve protein and energy, iron, vitamin B12, vitamin D, folate, and selected minerals such as zinc and magnesium. Their clinical consequences include anemia, impaired bone mineralization, immune dysfunction, delayed tissue repair, and overall deterioration in health status. The problem is particularly important in the pediatric population, in whom deficiencies may result in impaired growth and development. The aim of this review was to present the mechanisms leading to nutritional deficiencies in Crohn’s disease, discuss their clinical significance, and summarize current diagnostic and therapeutic strategies. The available evidence indicates that systematic nutritional assessment and appropriately selected nutritional interventions should constitute an integral part of comprehensive patient care.

  • Open Access

    Creatine Supplementation in Sport and Medicine: Efficacy, Safety, and Therapeutic Potential in the Light of Current Scientific Evidence

    by Agata WnęK, Alicja Biskup, Aleksandra Gniewkiewicz, Paulina Turzyńska, Zuzanna Hucała, Natasza Jankowska

    Creatine is a naturally occurring compound stored mainly in skeletal muscles, where it plays an essential role in energy production during high-intensity exercise. Creatine monohydrate is one of the most widely studied and effective ergogenic supplements, shown to improve strength, anaerobic performance, muscle mass, and recovery. This paper reviews the current evidence on the effectiveness, safety, and applications of creatine supplementation in sports and health. In addition to its well-established benefits for athletic performance, emerging research suggests potential roles in neuroprotection, healthy aging, and rehabilitation. Current evidence indicates that creatine monohydrate is safe for both short- and long-term use when consumed according to recommended guidelines.

  • Open Access

    Exercise-induced BDNF signaling mediates neuroplasticity in depression

    by Paulina Patrycja Turzyńska, Marcjanna Maria Liedtke, Alicja Biskup, Agata WnęK, Weronika Martynowska, Dastin Misiaszek, Natalia Grabowska, Anna Wolszczak

    Background.Major depressive disorder (MDD) is increasingly recognized as a disorder of impaired neuroplasticity. Brain-derived neurotrophic factor (BDNF) plays a central role in neuronal survival, synaptic plasticity, and antidepressant mechanisms [1–4]. Physical exercise has emerged as an effective non-pharmacological intervention capable of enhancing BDNF signaling and promoting neuroplastic adaptations [20–27]. Aim.To summarize current evidence on the role of exercise-induced BDNF signaling in mediating neuroplastic adaptations and antidepressant effects in depression. Material and methods.A narrative review of peer-reviewed studies, including mechanistic research, randomized controlled trials, cohort studies, and meta-analyses, was conducted. Evidence from neuroscience, exercise physiology, and clinical psychiatry was integrated. Results.Exercise increases BDNF expression through multiple biological pathways, including lactate signaling, muscle–brain crosstalk, and kynurenine metabolism [8–10]. These adaptations promote neurogenesis, synaptic plasticity, and improvements in brain connectivity [11,12,16,17]. Meta-analyses demonstrate that exercise increases circulating BDNF levels and reduces depressive symptoms [14,15,22]. Epidemiological and clinical studies indicate that higher physical activity is associated with a lower risk of depression and improved mental health outcomes [20–30]. Conclusions.BDNF appears to be a key mediator of the antidepressant effects of exercise. Current evidence supports the inclusion of structured physical activity as an evidence-based component of depression treatment, although further research is needed to optimize exercise protocols and clarify individual differences in BDNF responsiveness.

  • Open Access

    SARCOPENIC OBESITY IN THE ERA OF INCRETIN-BASED THERAPIES: DIAGNOSTIC CHALLENGES, THE RISK OF MUSCLE MASS LOSS, AND PREVENTION STRATEGIES

    by Anna Wolszczak, Weronika Martynowska, Michał Hajt, Dastin Misiaszek, Alicja Graczyk, Piotr Ciecierski, Natalia Grabowska, Jakub Motor, Paulina Patrycja Turzyńska

    Introduction and purpose. Sarcopenic obesity (SO) is defined by the coexistence of excess adiposity and reduced muscle mass and function and is associated with disability, frailty, cardiometabolic disease, and increased mortality. This review aims to summarize current evidence on the definition and diagnosis of SO, assess the effects of incretin-based therapies on body composition, with a focus on practical strategies to reduce the risk of clinically relevant muscle loss during obesity treatment. Material and methods. This manuscript was prepared as a structured narrative review based on publications identified in PubMed/MEDLINE, Google Scholar, and the Cochrane Library. Results. Current evidence suggests that semaglutide and tirzepatide produce significant and sustained reductions in body weight and fat mass, including visceral adipose tissue, while also being associated with a decrease in absolute lean body mass. These changes should not be interpreted automatically as clinically relevant skeletal muscle loss. However, older adults, frail individuals, and patients with low muscle reserve are more susceptible, especially without adequate protein intake, resistance exercise, and regular monitoring. Conclusions. Incretin-based therapies represent a major advance in obesity treatment; however, in patients at risk of SO, they should be used within a multimodal strategy aimed at preserving muscle mass and function.